Merck & Co., Inc. (NYSE:MRK) Stock Gets Price Target Cut from Royal Bank Of Canada

Key Points

• Royal Bank of Canada cut Merck’s price target from $145 to $140 while maintaining a “sector perform” rating, implying 6.73% downside from the prior close.
• Merck shares rose 2.6% to $150.10, while overall analyst sentiment remained positive: 17 analysts rate the stock a Buy, nine Hold, and one Sell, producing a “Moderate Buy” consensus and $152.96 average target.
• Merck reported third-quarter adjusted EPS of $2.49 and revenue of $18.09 billion, beating estimates, but investors remain focused on Keytruda’s patent cliff and generic competition expected to begin in 2027.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) had its price objective dropped by research analysts at Royal Bank Of Canada from $145.00 to $140.00 in a research report issued on Friday, Benzinga reports. The firm currently has a "sector perform" rating on the stock. Royal Bank Of Canada's price target would indicate a potential downside of 6.73% from the company's previous close.

MRK has been the topic of several other research reports. Weiss Ratings raised shares of Merck & Co., Inc. from a "hold (c-)" rating to a "hold (c)" rating in a report on Tuesday, August 25th. TD Cowen raised their price objective on shares of Merck & Co., Inc. from $137.00 to $155.00 and gave the company a "hold" rating in a research report on Wednesday, September 23rd. Barclays lifted their price objective on shares of Merck & Co., Inc. from $150.00 to $180.00 and gave the stock an "overweight" rating in a report on Monday. Jefferies Financial Group upped their target price on shares of Merck & Co., Inc. from $152.00 to $175.00 and gave the stock a "buy" rating in a research report on Thursday, August 20th. Finally, Rothschild & Co Redburn increased their price objective on Merck & Co., Inc. from $140.00 to $145.00 and gave the company a "buy" rating in a research report on Monday, July 6th. Seventeen analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $152.96.

Merck & Co., Inc. Stock Up 2.6%

Shares of MRK traded up $3.77 during trading hours on Friday, hitting $150.10. The stock had a trading volume of 4,694,865 shares, compared to its average volume of 10,637,644. The firm has a market capitalization of $370.32 billion, a P/E ratio of 120.18, a price-to-earnings-growth ratio of 6.49 and a beta of 0.21. Merck & Co., Inc. has a 1-year low of $82.01 and a 1-year high of $156.92. The firm has a 50 day simple moving average of $146.89 and a 200-day simple moving average of $126.49. The company has a debt-to-equity ratio of 1.22, a current ratio of 1.32 and a quick ratio of 1.10.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last issued its quarterly earnings data on Thursday, October 29th. The company reported $2.49 EPS for the quarter, topping analysts' consensus estimates of $2.09 by $0.40. The firm had revenue of $18.09 billion during the quarter, compared to analyst estimates of $17.33 billion. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%. The company's revenue for the quarter was up 4.7% on a year-over-year basis. During the same period in the previous year, the company posted $2.58 EPS. Sell-side analysts predict that Merck & Co., Inc. will post 2.64 EPS for the current fiscal year.

Insider Activity at Merck & Co., Inc.

In related news, EVP Jennifer Zachary sold 80,315 shares of the firm's stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $133.46, for a total transaction of $10,718,839.90. Following the completion of the transaction, the executive vice president owned 45,509 shares of the company's stock, valued at $6,073,631.14. This trade represents a 63.83% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Richard Deluca sold 20,784 shares of the stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $130.43, for a total transaction of $2,710,857.12. Following the transaction, the executive vice president owned 134,703 shares in the company, valued at approximately $17,569,312.29. This trade represents a 13.37% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 228,238 shares of company stock worth $29,977,783 over the last 90 days. 0.17% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Merck & Co., Inc.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Curry Webb Wealth Management LLC bought a new stake in Merck & Co., Inc. during the 3rd quarter valued at $29,000. Horizons Wealth Management purchased a new stake in Merck & Co., Inc. in the third quarter valued at $30,000. Bullseye Investment Management LLC purchased a new position in Merck & Co., Inc. during the second quarter valued at approximately $27,000. Graney & King LLC boosted its holdings in Merck & Co., Inc. by 400.0% during the second quarter. Graney & King LLC now owns 250 shares of the company's stock worth $32,000 after buying an additional 200 shares in the last quarter. Finally, Foresight Capital Management Advisors Inc. acquired a new stake in Merck & Co., Inc. in the third quarter valued at approximately $43,000. Hedge funds and other institutional investors own 76.07% of the company's stock.

Key Stories Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck reported adjusted third-quarter earnings of $2.49 per share, well above the $2.09 analyst consensus, while revenue rose 4.7% year over year to $18.09 billion versus expectations of $17.33 billion. Merck tops quarterly estimates, hikes profit outlook
• Positive Sentiment: Management raised its 2026 sales and adjusted profit outlook, signaling confidence that Keytruda, the newer Keytruda Qlex formulation and recently launched products can offset pressure from older medicines. Keytruda-related sales and WINREVAIR were notable growth drivers. Merck Q3 Earnings Call Highlights Pipeline Progress and Raised Outlook
• Positive Sentiment: Merck reported encouraging endometrial-cancer data: KEYTRUDA reduced the risk of disease progression, while sacituzumab tirumotecan produced positive late-stage results. The FDA also granted priority review to the latter’s application, strengthening the company’s pipeline outlook. Merck Turns Heads With Phase 3 Endometrial Cancer Data
• Positive Sentiment: Guggenheim raised its price target to $171 and maintained a Buy rating, implying further potential upside and adding support to the positive market reaction. Guggenheim Merck rating
• Neutral Sentiment: Merck remains attractive to income-oriented investors because of its dividend, but commentary cautions that dividend safety and yield should be assessed alongside the company’s patent and product-cycle risks. Merck dividend analysis
• Negative Sentiment: Investors continue to look beyond the earnings beat because Keytruda faces a patent cliff and generic headwinds beginning in 2027. Some reported revenue growth also benefited from the timing of customer purchases, suggesting underlying growth was less robust.

About Merck & Co., Inc.

Merck & Co, Inc is a global healthcare company that develops, manufactures and markets prescription medicines, vaccines and animal-health products. Its pharmaceutical business focuses on oncology, infectious diseases, cardiology, immunology and other areas of significant medical need. The company serves patients, healthcare providers and institutions in markets worldwide.

Merck's principal products include Keytruda, an immunotherapy used to treat a range of cancers; Gardasil and Gardasil 9, vaccines that help protect against human papillomavirus; and Januvia and Janumet, medicines used to manage type 2 diabetes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.